CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 129 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2018. The put-call ratio across all filers is 0.57 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $2,000 | -89.5% | 28,540 | -43.4% | 0.00% | – |
| Q3 2018 | $19,000 | -13.6% | 50,415 | 0.0% | 0.00% | – |
| Q2 2018 | $22,000 | -83.7% | 50,415 | -12.3% | 0.00% | -100.0% |
| Q1 2018 | $135,000 | -77.0% | 57,515 | -72.3% | 0.00% | -80.0% |
| Q4 2017 | $588,000 | -10.8% | 207,515 | -10.1% | 0.01% | -16.7% |
| Q3 2017 | $659,000 | +16.0% | 230,715 | -0.0% | 0.01% | +20.0% |
| Q2 2017 | $568,000 | -33.8% | 230,780 | -4.1% | 0.01% | -37.5% |
| Q1 2017 | $858,000 | -1.3% | 240,680 | -2.9% | 0.01% | -11.1% |
| Q4 2016 | $869,000 | -9.4% | 247,870 | +4.1% | 0.01% | -18.2% |
| Q3 2016 | $959,000 | -9.9% | 238,095 | -2.6% | 0.01% | -15.4% |
| Q2 2016 | $1,064,000 | +13.2% | 244,345 | -1.3% | 0.01% | +333.3% |
| Q1 2016 | $940,000 | +33.5% | 247,570 | +456.7% | 0.00% | -62.5% |
| Q4 2015 | $704,000 | +46.7% | 44,470 | -1.8% | 0.01% | +33.3% |
| Q3 2015 | $480,000 | – | 45,274 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ridgeback Capital Investments L.P. | 1,025,000 | $24,815,000 | 31.36% |
| TSP Capital Management Group, LLC | 836,342 | $20,248,000 | 8.80% |
| Iguana Healthcare Management, LLC | 200,000 | $4,842,000 | 2.76% |
| First Light Asset Management, LLC | 116,096 | $2,811,000 | 2.38% |
| SECTORAL ASSET MANAGEMENT INC | 2,227,688 | $53,932,000 | 2.33% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 550,735 | $13,334,000 | 2.05% |
| Eventide Asset Management | 257,000 | $6,222,000 | 1.92% |
| Redmile Group, LLC | 397,951 | $9,634,000 | 1.19% |
| ARDSLEY ADVISORY PARTNERS LP | 357,000 | $8,643,000 | 1.15% |
| Rhenman & Partners Asset Management AB | 90,000 | $2,179,000 | 0.85% |